Relapsed/refractory non-Hodgkin lymphoma

Clinical trials for Relapsed/refractory non-Hodgkin lymphoma explained in plain language.

Never miss a new study

Get alerted when new Relapsed/refractory non-Hodgkin lymphoma trials appear

Sign up with your email to follow new studies for Relapsed/refractory non-Hodgkin lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 2 Not yet recruiting 1 Not yet finished but already full! 1 Completed 1

New cell therapy takes aim at Hard-to-Treat blood cancers

Disease control Not yet recruiting

This early-stage study tests a new treatment called LVIVO-TaVec122 in 48 adults with B-cell blood cancers that have come back or not responded to standard therapy. The main goals are to check safety, find the right dose, and measure how long the treatment lasts in the body. It is…

Matched conditions: RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA

Phase 1 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control

Last updated Jun 27, 2026 13:03 UTC

Relapsed/refractory non-Hodgkin lymphoma

Get alerted when new Relapsed/refractory non-Hodgkin lymphoma trials appear

New cell therapy takes aim at Hard-to-Treat blood cancers